GLORIA — GEOMAR Library Ocean Research Information Access

Hits per page

hits 1 - 3 | 3 hits

Sorting

Online Resource

Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study

Gram, Mie Agermose ; Nielsen, Jens ; Schelde, Astrid Blicher ; [et al.]

Public Library of Science (PLoS) ; 2021

In: PLOS Medicine Vol. 18, No. 12 ( 2021-12-17), p. e1003874-

add to mindlist on the mindlist

Details

In: PLOS Medicine, Public Library of Science (PLoS), Vol. 18, No. 12 ( 2021-12-17), p. e1003874-

Abstract: The recommendations in several countries to stop using the ChAdOx1 vaccine has led to vaccine programs combining different Coronavirus Disease 2019 (COVID-19) vaccine types, which necessitates knowledge on vaccine effectiveness (VE) of heterologous vaccine schedules. The aim of this Danish nationwide population-based cohort study was therefore to estimate the VE against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and COVID-19–related hospitalization and death following the first dose of the ChAdOx1 vaccine and the combination of the ChAdOx1/mRNA vaccines. Methods and findings All individuals alive in or immigrating to Denmark from 9 February 2021 to 23 June 2021 were identified in the Danish Civil Registration System. Information on exposure, outcomes, and covariates was obtained from Danish national registries. Poisson and Cox regression models were used to calculate crude and adjusted VE, respectively, along with 95% confidence intervals (CIs) against SARS-CoV-2 infection and COVID-19–related hospitalization or death comparing vaccinated versus unvaccinated individuals. The VE estimates were adjusted for calendar time as underlying time and for sex, age, comorbidity, country of origin, and hospital admission. The analyses included 5,542,079 individuals (97.6% of the total Danish population). A total of 144,360 individuals were vaccinated with the ChAdOx1 vaccine as the first dose, and of these, 136,551 individuals received an mRNA vaccine as the second dose. A total of 1,691,464 person-years and 83,034 SARS-CoV-2 infections were included. The individuals vaccinated with the first dose of the ChAdOx1 vaccine dose had a median age of 45 years. The study population was characterized by an equal distribution of males and females; 6.7% and 9.2% originated from high-income and other countries, respectively. The VE against SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine was 88% (95% CI: 83; 92) 14 days after the second dose and onwards. There were no COVID-19–related hospitalizations or deaths among the individuals vaccinated with the combined vaccine schedule during the study period. Study limitations including unmeasured confounders such as risk behavior and increasing overall vaccine coverage in the general population creating herd immunity are important to take into consideration when interpreting the results. Conclusions In this study, we observed a large reduction in the risk of SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine, compared with unvaccinated individuals.

Type of Medium: Online Resource

ISSN: 1549-1676

URL: Article

DOI: 10.1371/journal.pmed.1003874

DOI: 10.1371/journal.pmed.1003874.g001

DOI: 10.1371/journal.pmed.1003874.g002

DOI: 10.1371/journal.pmed.1003874.g003

DOI: 10.1371/journal.pmed.1003874.t001

DOI: 10.1371/journal.pmed.1003874.t002

DOI: 10.1371/journal.pmed.1003874.t003

DOI: 10.1371/journal.pmed.1003874.s001

DOI: 10.1371/journal.pmed.1003874.s002

DOI: 10.1371/journal.pmed.1003874.s003

DOI: 10.1371/journal.pmed.1003874.s004

DOI: 10.1371/journal.pmed.1003874.s005

DOI: 10.1371/journal.pmed.1003874.s006

DOI: 10.1371/journal.pmed.1003874.s007

DOI: 10.1371/journal.pmed.1003874.r001

DOI: 10.1371/journal.pmed.1003874.r002

DOI: 10.1371/journal.pmed.1003874.r003

DOI: 10.1371/journal.pmed.1003874.r004

DOI: 10.1371/journal.pmed.1003874.r005

DOI: 10.1371/journal.pmed.1003874.r006

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2021

detail.hit.zdb_id: 2164823-2

Permalink

	Location	Call Number	Limitation	Availability

Others were also interested in ...

Online Resource

Link to publisher

Online Resource

Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study

Nielsen, Katrine Finderup ; Moustsen-Helms, Ida Rask ; Schelde, Astrid Blicher ; [et al.]

Public Library of Science (PLoS) ; 2022

In: PLOS Medicine Vol. 19, No. 11 ( 2022-11-22), p. e1004037-

add to mindlist on the mindlist

Details

In: PLOS Medicine, Public Library of Science (PLoS), Vol. 19, No. 11 ( 2022-11-22), p. e1004037-

Abstract: Individuals with a prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection have a moderate to high degree of protection against reinfection, though seemingly less so when the Omicron variant of SARS-CoV-2 started to circulate. The aim of this study was to evaluate the vaccine effectiveness (VE) against SARS-CoV-2 reinfection, Coronavirus Disease 2019 (COVID-19)-related hospitalization, and COVID-19-related death, in individuals with prior SARS-CoV-2 infection, and to assess the effect of time since vaccination during periods with different dominant SARS-CoV-2 variants. Methods and findings This study used a nationwide cohort design including all individuals with a confirmed SARS-CoV-2 infection, who were alive, and residing in Denmark between 1 January 2020 and 31 January 2022. Using Danish nationwide registries, we obtained information on SARS-CoV-2 infections, COVID-19 vaccination, age, sex, comorbidity, staying at hospital, and country of origin. The study population included were individuals with prior SARS-CoV-2 infection. Estimates of VE against SARS-CoV-2 reinfection with 95% confidence intervals (CIs) were calculated using a Poisson regression model and adjusted for age, sex, country of origin, comorbidity, staying at hospital, calendar time, and test incidence using a Cox regression model. The VE estimates were calculated separately for three periods with different dominant SARS-CoV-2 variants (Alpha (B.1.1.7), Delta (B.1.617.2), or Omicron (B.1.1.529)) and by time since vaccination using unvaccinated as the reference. In total, 148,527 person-years and 44,192 SARS-CoV-2 infections were included for the analysis regarding reinfections. The study population comprised of 209,814 individuals infected before or during the Alpha period, 292,978 before or during the Delta period, and 245,530 before or during the Omicron period. Of these, 40,281 individuals had completed their primary vaccination series during the Alpha period (19.2%), 190,026 during the Delta period (64.9%), and 158,563 during the Omicron period (64.6%). VE against reinfection following any COVID-19 vaccine type administered in Denmark, peaked at 71% (95% CI: -Inf to 100%) at 104 days or more after vaccination during the Alpha period, 94% (95% CI: 92% to 96%) 14 to 43 days after vaccination during the Delta period, and 60% (95% CI: 58% to 62%) 14 to 43 days after vaccination during the Omicron period. Waning immunity following vaccination was observed and was most pronounced during the Omicron period. Due to too few events, it was not possible to estimate VE for hospitalization and death. Study limitations include potentially undetected reinfections, differences in health-seeking behavior, or risk behavior between the compared groups. Conclusions This study shows that in previously infected individuals, completing a primary vaccination series was associated with a significant protection against SARS-CoV-2 reinfection compared with no vaccination. Even though vaccination seems to protect to a lesser degree against reinfection with the Omicron variant, these findings are of public health relevance as they show that previously infected individuals still benefit from COVID-19 vaccination in all three variant periods.

Type of Medium: Online Resource

ISSN: 1549-1676

URL: Article

DOI: 10.1371/journal.pmed.1004037

DOI: 10.1371/journal.pmed.1004037.g001

DOI: 10.1371/journal.pmed.1004037.t001

DOI: 10.1371/journal.pmed.1004037.t002

DOI: 10.1371/journal.pmed.1004037.s001

DOI: 10.1371/journal.pmed.1004037.s002

DOI: 10.1371/journal.pmed.1004037.s003

DOI: 10.1371/journal.pmed.1004037.s004

DOI: 10.1371/journal.pmed.1004037.s005

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2022

detail.hit.zdb_id: 2164823-2

Permalink

	Location	Call Number	Limitation	Availability

Others were also interested in ...

Online Resource

Link to publisher

Online Resource

Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

Gram, Mie Agermose ; Emborg, Hanne-Dorthe ; Schelde, Astrid Blicher ; [et al.]

Public Library of Science (PLoS) ; 2022

In: PLOS Medicine Vol. 19, No. 9 ( 2022-9-1), p. e1003992-

add to mindlist on the mindlist

Details

In: PLOS Medicine, Public Library of Science (PLoS), Vol. 19, No. 9 ( 2022-9-1), p. e1003992-

Abstract: The continued occurrence of more contagious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants and waning immunity over time require ongoing reevaluation of the vaccine effectiveness (VE). This study aimed to estimate the effectiveness in 2 age groups (12 to 59 and 60 years or above) of 2 or 3 vaccine doses (BNT162b2 mRNA or mRNA-1273) by time since vaccination against SARS-CoV-2 infection and Coronavirus Disease 2019 (COVID-19) hospitalization in an Alpha-, Delta-, or Omicron-dominated period. Methods and findings A Danish nationwide cohort study design was used to estimate VE against SARS-CoV-2 infection and COVID-19 hospitalization with the Alpha, Delta, or Omicron variant. Information was obtained from nationwide registries and linked using a unique personal identification number. The study included all previously uninfected residents in Denmark aged 12 years or above (18 years or above for the analysis of 3 doses) in the Alpha (February 20 to June 15, 2021), Delta (July 4 to November 20, 2021), and Omicron (December 21, 2021 to January 31, 2022) dominated periods. VE estimates including 95% confidence intervals (CIs) were calculated (1-hazard ratio∙100) using Cox proportional hazard regression models with underlying calendar time and adjustments for age, sex, comorbidity, and geographical region. Vaccination status was included as a time-varying exposure. In the oldest age group, VE against infection after 2 doses was 90.7% (95% CI: 88.2; 92.7) for the Alpha variant, 82.3% (95% CI: 75.5; 87.2) for the Delta variant, and 39.9% (95% CI: 26.3; 50.9) for the Omicron variant 14 to 30 days since vaccination. The VE waned over time and was 73.2% (Alpha, 95% CI: 57.1; 83.3), 50.0% (Delta, 95% CI: 46.7; 53.0), and 4.4% (Omicron, 95% CI: −0.1; 8.7) 〉 120 days since vaccination. Higher estimates were observed after the third dose with VE estimates against infection of 86.1% (Delta, 95% CI: 83.3; 88.4) and 57.7% (Omicron, 95% CI: 55.9; 59.5) 14 to 30 days since vaccination. Among both age groups, VE against COVID-19 hospitalization 14 to 30 days since vaccination with 2 or 3 doses was 98.1% or above for the Alpha and Delta variants. Among both age groups, VE against COVID-19 hospitalization 14 to 30 days since vaccination with 2 or 3 doses was 95.5% or above for the Omicron variant. The main limitation of this study is the nonrandomized study design including potential differences between the unvaccinated (reference group) and vaccinated individuals. Conclusions Two vaccine doses provided high protection against SARS-CoV-2 infection and COVID-19 hospitalization with the Alpha and Delta variants with protection, notably against infection, waning over time. Two vaccine doses provided only limited and short-lived protection against SARS-CoV-2 infection with Omicron. However, the protection against COVID-19 hospitalization following Omicron SARS-CoV-2 infection was higher. The third vaccine dose substantially increased the level and duration of protection against infection with the Omicron variant and provided a high level of sustained protection against COVID-19 hospitalization among the +60-year-olds.

Type of Medium: Online Resource

ISSN: 1549-1676

URL: Article

DOI: 10.1371/journal.pmed.1003992

DOI: 10.1371/journal.pmed.1003992.g001

DOI: 10.1371/journal.pmed.1003992.g002

DOI: 10.1371/journal.pmed.1003992.g003

DOI: 10.1371/journal.pmed.1003992.g004

DOI: 10.1371/journal.pmed.1003992.t001

DOI: 10.1371/journal.pmed.1003992.t002

DOI: 10.1371/journal.pmed.1003992.t003

DOI: 10.1371/journal.pmed.1003992.t004

DOI: 10.1371/journal.pmed.1003992.t005

DOI: 10.1371/journal.pmed.1003992.s001

DOI: 10.1371/journal.pmed.1003992.s002

DOI: 10.1371/journal.pmed.1003992.s003

DOI: 10.1371/journal.pmed.1003992.s004

DOI: 10.1371/journal.pmed.1003992.s005

DOI: 10.1371/journal.pmed.1003992.s006

DOI: 10.1371/journal.pmed.1003992.s007

DOI: 10.1371/journal.pmed.1003992.s008

DOI: 10.1371/journal.pmed.1003992.s009

DOI: 10.1371/journal.pmed.1003992.r001

DOI: 10.1371/journal.pmed.1003992.r002

DOI: 10.1371/journal.pmed.1003992.r003

DOI: 10.1371/journal.pmed.1003992.r004

DOI: 10.1371/journal.pmed.1003992.r005

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2022

detail.hit.zdb_id: 2164823-2

Permalink

	Location	Call Number	Limitation	Availability

Others were also interested in ...

Online Resource

Link to publisher

hits 1 - 3 | 3 hits